Atlas Trials

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

Clinical trial NCT03732820 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03732820
Sponsor
AstraZeneca
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Metastatic Castration-resistant Prostate Cancer
Start date
2018-10-31
Primary completion
2021-07-30
Enrollment
895

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.